PRESS RELEASES

Nyxoah to Delay Full Year 2020 Earnings Release Until April 9, 2021

Nyxoah to Delay Full Year 2020 Earnings Release Until April 9, 2021

Mont-Saint-Guibert, Belgium – 2 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announced that it will delay its full year 2020 earnings release and subsequent conference call, previously scheduled for April 6, 2021.  The Company now intends to report full year financial results for the year ended December 31, 2020 on Friday, April 9, 2021, before the market opens. The Company will host a conference call to discuss full year 2020 financial results on the same day at 3:00 p.m. CET / 9:00 a.m. ET. The details for the conference call can be found below. The delay is required for the Company and its auditors to complete final audit procedures in accordance with PCAOB auditing standards.

Full Year 2020 Financial Results Conference Call:

Date: Friday, April 9, 2021
Time: 3:00 p.m. CET / 9:00 a.m. ET
Webcast: https://channel.royalcast.com/landingpage/nyxoah/20210409_1/

For further information, please contact:
Nyxoah
Fabian Suarez, Chief Financial Officer
[email protected]
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
[email protected]com

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk2 and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit www.nyxoah.com.

Attachment

Latest News

TigerGraph Continues to Drive Graph Analytics and AI Market Momentum, Unveils TigerGraph Cloud on Google Cloud Platform and Expanded Global Developer Community

Graph Leader Also Reveals Connectors for Snowflake and Tableau, Announces Hackathon Winners, and Shares Early Release of Graph-Powered Analytics Book at Graph + AI Summit 2021 REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) — TigerGraph, provider of the leading graph analytics platform, today announced that the company continues to accelerate the adoption, application, and […]

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

Over 5000 Patients Enrolled in 20 countries EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) — Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant […]

ACAMS’ 12th Annual AML & Anti-Financial Crime Conference – APAC Takes Cutting-Edge Look at the Perils and Promise of Compliance Efforts in the Asia Pacific Region

Financial-crime prevention experts from the Hong Kong Monetary Authority, Monetary Authority of Singapore, Anti-Money Laundering Council (AMLC) of the Philippines, British Consulate-General Hong Kong, Homeland Security Investigations, U.S. Consulate General Hong Kong, and APAC’s leading financial institutions will share mitigation strategies on money laundering, sanctions, corruption, bribery and other regulatory challenges Hong Kong / Singapore, […]